NCT03823131View on ClinicalTrials.gov

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaUnresectable Head and Neck Squamous Cell Carcinoma
Interventions
DEVICE

ImmunoPulse

Intratumoral

DRUG

Epacadostat

Given PO

DRUG

Pembrolizumab

Given IV

BIOLOGICAL

CORVax

Intratumoral

DRUG

Tavokinogene telseplasmid

Intratumoral

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

OncoSec Medical Incorporated

INDUSTRY

lead

Chase Heaton, MD

OTHER